10-year Temporal Trends of Intravenous Thrombolysis in Acute Ischemic Stroke: Analysis of the China National Stroke Registry I-Ⅲ

J Stroke Cerebrovasc Dis. 2024 Jan;33(1):107431. doi: 10.1016/j.jstrokecerebrovasdis.2023.107431. Epub 2023 Nov 9.

Abstract

Objectives: To investigate the 10-year trend in healthcare quality of intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator in acute ischemic stroke (AIS) in China.

Materials and methods: We analyzed 42,188 AIS within 7 days of onset from the China National Stroke Registry (CNSR) Ⅰ-Ⅲ. Primary outcomes were temporal changes in the proportion of patients arriving at the hospital within 3.5 hours (and 2 hours) of onset and receiving IVT within 4.5 hours (and 3 hours), stratified by region and hospital tier. Secondary outcomes included temporal changes in door-to-needle time (DNT), DNT ≤60 min and favorable outcome defined as a 90-day modified Rankin Scale (mRS) of 0-1.

Results: Among patients arriving at the hospital within 3.5 hours of onset, 13.5%, 7.1% and 33.4% patients received IVT within 4.5 hours in CNSR Ⅰ, Ⅱ and Ⅲ, respectively, including a higher proportion from eastern China (37.0%) and tertiary hospitals (36.5%). The median DNT was shorter in CNSR Ⅲ (60.0 min) than those in Ⅱ (95.0 min) and I (94.0 min). The proportion of patients with DNT ≤60 min was greater in Ⅲ (53.4%) than those in Ⅱ (26.7%) and Ⅰ (13.4%). The proportion of favorable outcomes was higher in CNSR Ⅲ (72.8%) than those in Ⅱ (49.6%) and Ⅰ (49.4%). Similar trends were observed for patients arriving at the hospital within 2 hours and receiving IVT within 3 hours of onset.

Conclusions: The healthcare quality of IVT has improved remarkably in the past decade, notably in eastern China and tertiary hospitals.

Keywords: Acute ischemic stroke; China; Healthcare quality; Intravenous thrombolysis; Recombinant tissue plasminogen activator.

MeSH terms

  • Brain Ischemia* / diagnosis
  • Brain Ischemia* / drug therapy
  • China
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Ischemic Stroke* / drug therapy
  • Registries
  • Stroke* / diagnosis
  • Stroke* / drug therapy
  • Tertiary Care Centers
  • Thrombolytic Therapy / adverse effects
  • Time-to-Treatment
  • Tissue Plasminogen Activator / adverse effects
  • Treatment Outcome

Substances

  • Tissue Plasminogen Activator
  • Fibrinolytic Agents